These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38091991)

  • 1. Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting.
    Wei J; Lotfy P; Faizi K; Baungaard S; Gibson E; Wang E; Slabodkin H; Kinnaman E; Chandrasekaran S; Kitano H; Durrant MG; Duffy CV; Pawluk A; Hsu PD; Konermann S
    Cell Syst; 2023 Dec; 14(12):1087-1102.e13. PubMed ID: 38091991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells.
    Kelley CP; Haerle MC; Wang ET
    Cell Rep; 2022 Aug; 40(7):111226. PubMed ID: 35977479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cas13d: A New Molecular Scissor for Transcriptome Engineering.
    Gupta R; Ghosh A; Chakravarti R; Singh R; Ravichandiran V; Swarnakar S; Ghosh D
    Front Cell Dev Biol; 2022; 10():866800. PubMed ID: 35433685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d.
    Zhang C; Konermann S; Brideau NJ; Lotfy P; Wu X; Novick SJ; Strutzenberg T; Griffin PR; Hsu PD; Lyumkis D
    Cell; 2018 Sep; 175(1):212-223.e17. PubMed ID: 30241607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of on-target and off-target activity of CRISPR-Cas13d guide RNAs using deep learning.
    Wessels HH; Stirn A; Méndez-Mancilla A; Kim EJ; Hart SK; Knowles DA; Sanjana NE
    Nat Biotechnol; 2024 Apr; 42(4):628-637. PubMed ID: 37400521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System.
    Nguyen H; Wilson H; Jayakumar S; Kulkarni V; Kulkarni S
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches.
    Cheng X; Li Z; Shan R; Li Z; Wang S; Zhao W; Zhang H; Chao L; Peng J; Fei T; Li W
    Nat Commun; 2023 Feb; 14(1):752. PubMed ID: 36765063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13.
    Burris BJD; Molina Vargas AM; Park BJ; O'Connell MR
    Methods; 2022 Oct; 206():58-68. PubMed ID: 35987443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collateral activity of the CRISPR/RfxCas13d system in human cells.
    Shi P; Murphy MR; Aparicio AO; Kesner JS; Fang Z; Chen Z; Trehan A; Guo Y; Wu X
    Commun Biol; 2023 Mar; 6(1):334. PubMed ID: 36977923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CASowary: CRISPR-Cas13 guide RNA predictor for transcript depletion.
    Krohannon A; Srivastava M; Rauch S; Srivastava R; Dickinson BC; Janga SC
    BMC Genomics; 2022 Mar; 23(1):172. PubMed ID: 35236300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.
    Konermann S; Lotfy P; Brideau NJ; Oki J; Shokhirev MN; Hsu PD
    Cell; 2018 Apr; 173(3):665-676.e14. PubMed ID: 29551272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massively parallel profiling of RNA-targeting CRISPR-Cas13d.
    Kuo HC; Prupes J; Chou CW; Finkelstein IJ
    Nat Commun; 2024 Jan; 15(1):498. PubMed ID: 38216559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas13d-Mediated Microbial RNA Knockdown.
    Zhang K; Zhang Z; Kang J; Chen J; Liu J; Gao N; Fan L; Zheng P; Wang Y; Sun J
    Front Bioeng Biotechnol; 2020; 8():856. PubMed ID: 32850723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs.
    Zhang Y; Nguyen TM; Zhang XO; Wang L; Phan T; Clohessy JG; Pandolfi PP
    Genome Biol; 2021 Jan; 22(1):41. PubMed ID: 33478577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
    Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
    Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of length and sequence of gRNA on Cas13b and Cas13d activity in vitro and in vivo.
    Liu Y; Jing P; Zhou Y; Zhang J; Shi J; Zhang M; Yang H; Fei J
    Biotechnol J; 2023 Sep; 18(9):e2300002. PubMed ID: 37148478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas13 Precision Transcriptome Engineering in Cancer.
    Granados-Riveron JT; Aquino-Jarquin G
    Cancer Res; 2018 Aug; 78(15):4107-4113. PubMed ID: 30021724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
    Tong H; Huang J; Xiao Q; He B; Dong X; Liu Y; Yang X; Han D; Wang Z; Wang X; Ying W; Zhang R; Wei Y; Xu C; Zhou Y; Li Y; Cai M; Wang Q; Xue M; Li G; Fang K; Zhang H; Yang H
    Nat Biotechnol; 2023 Jan; 41(1):108-119. PubMed ID: 35953673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized CRISPR-RfxCas13d system for RNA targeting in zebrafish embryos.
    Hernandez-Huertas L; Kushawah G; Diaz-Moscoso A; Tomas-Gallardo L; Moreno-Sanchez I; da Silva Pescador G; Bazzini AA; Moreno-Mateos MA
    STAR Protoc; 2022 Mar; 3(1):101058. PubMed ID: 35005640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitous and Tissue-specific RNA Targeting in Drosophila Melanogaster using CRISPR/CasRx.
    Sun R; Brogan D; Buchman A; Yang T; Akbari OS
    J Vis Exp; 2021 Feb; (168):. PubMed ID: 33616113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.